Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 9102 results

  1. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  2. Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 1 July 2026.

    Technology appraisal guidance
    In consultation

  3. Novel risk profiling technologies to guide adjuvant chemotherapy decisions in early breast cancer

    Awaiting development Reference number: GID-HTG10904 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  4. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.

    Technology appraisal guidance
    In consultation

  5. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    Awaiting development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over

    Awaiting development Reference number: GID-TA12446 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date:  20 August 2026

    NICE guideline
    In development

  10. Aggressive behaviour in people receiving NHS or social care: prevention and management

    In development Reference number: GID-NG10432 Expected publication date:  28 January 2027

    NICE guideline
    In development

  11. Autologous platelet-rich plasma (PRP) injection of the lumbar facet (zygapophyseal) joints, via the intra-articular or medial branch route, for lumbar facet joint pain

    Topic prioritisation

    HealthTech guidance
    Topic prioritisation

  12. LATERA absorbable nasal implant for Nasal valve collapse causing nasal obstruction

    Topic prioritisation

    HealthTech guidance
    Topic prioritisation

  13. Cryoablation for abdominal wall endometriosis

    Topic prioritisation

    HealthTech guidance
    Topic prioritisation

  14. Ultrasound-guided transcervical and transvaginal radiofrequency ablation for symptomatic uterine fibroids

    In development Reference number: GID-HTG10470 Expected publication date:  18 June 2027

    HealthTech guidance
    In development

  15. Transvaginal radiofrequency ablation for symptomatic uterine fibroids

    In development Reference number: GID-HTG10538 Expected publication date: TBC

    HealthTech guidance
    In development